AWA
MRNA icon

Arete Wealth Advisors’s Moderna MRNA Stock Holding History

Arete Wealth Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,501
Closed -$247K – 597
2023
Q4 		$247K Buy
+2,501
New +$210K 0.02% 600
2023
Q3 		– Sell
-3,139
Closed -$381K – 631
2023
Q2 		$381K Buy
3,139
+451
+17% +$60.2K 0.03% 425
2023
Q1 		$413K Buy
2,688
+843
+46% +$139K 0.03% 387
2022
Q4 		$331M Buy
1,845
+125
+7% +$20.4K 0.03% 430
2022
Q3 		$203K Sell
1,720
-50
-3% -$7.59K 0.02% 516
2022
Q2 		$253K Buy
+1,770
New +$253K 0.03% 372
2022
Q1 		– Sell
-1,824
Closed -$447K – 539
2021
Q4 		$447K Sell
1,824
-359
-16% -$105K 0.04% 304
2021
Q3 		$834K Buy
+2,183
New +$805K 0.09% 186

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Arete Wealth Advisors's MRNA Position: Q1 2024 in Review

Arete Wealth Advisors sold out of Moderna (MRNA) in Q1 2024, closing a stake of 2,501 shares — an estimated $247K sold.

Arete Wealth Advisors first reported a position in MRNA in Q3 2021 and held it in 8 quarters. The position peaked at $331M in Q4 2022. 902 funds tracked by Wall St. Rank hold MRNA as of Q1 2024.

  • Arete Wealth Advisors reported no remaining Moderna position as of Q1 2024 after selling out during the quarter.
  • Arete Wealth Advisors sold 2,501 Moderna shares in Q1 2024, an estimated $247K.
  • Arete Wealth Advisors first reported a position in Moderna in Q3 2021 and held it in 8 quarters.
  • Arete Wealth Advisors's Moderna position peaked at $331M in Q4 2022.
  • 902 funds tracked by Wall St. Rank held Moderna as of Q1 2024.

Based on Arete Wealth Advisors's 13F filing for Q1 2024, filed 16 May 2024.